A medication to delay type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a medication (called a GLP-1 receptor agonist) to see if it can help people in the earliest stage of type 1 diabetes keep their insulin-making cells working longer. It might help delay the need for insulin injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage 1 type 1 diabetes, meaning you have autoantibodies but your blood sugar is still normal.
- You have not had any episodes of very low blood sugar (severe hypoglycemia) in the past 3 months.
- You have not had pancreatitis (inflammation of the pancreas) and do not have a family history of a rare thyroid cancer called medullary thyroid cancer.
- You are not pregnant or breastfeeding and, if you are of childbearing age, you agree to use effective birth control.
- Your weight is not too low: for adults, BMI of at least 18.5; for children, weight not below the 5th percentile.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a GLP-1 receptor agonist (a type of medicine that helps control blood sugar and appetite) can improve metabolic health in people with early type 1 diabetes. It may be an option if you have already taken teplizumab to delay the disease or were recently diagnosed with type 1 diabetes.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests whether a GLP-1 medication (a type of drug that helps with weight loss) can safely and effectively help young adults with type 1 diabetes who also have obesity. It aims to see if adding this treatment to insulin can improve weight and blood sugar control.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This trial tests whether adding a weekly semaglutide injection (a GLP-1 drug) to a closed-loop insulin system can help reduce the need for carb counting in people with type 1 diabetes. It aims to improve blood sugar control and make diabetes management easier.
Hear when a new Stage 1 Diabetes Mellitus, Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.